gip glp 1 glucagon agonists Frontiers GLP-1: Actions on Beta-cell Mass

Discussion In this study of 606 434 people (protocol 1 and protocol 2 combined) evaluating both treatment initiation and treatment adherence effects over a median of three yearstotalling 1 559 238 person years, GLP-1 receptor agonist use (versus SGLT-2 inhibitor use) was consistently associated with a reduced risk of developing various SUDs, including disorders related to alcohol use, cannabis use, cocaine use, nicotine use, and opioids use, and other SUDs

Similarly, kefir, a multi-species probiotic beverage, modulates gut bacterial and fungal communities, suppresses hepatic steatosis, and reduces pro-inflammatory markers in HFD-fed mice 160,161

Liposomes are tailored to encapsulate hydrophobic or hydrophilic drugs, but the structural compatibility between the drug and the liposome is crucial [342]

Looking to give IV glutathione therapy a shot